MTB by GeneXpert – Bronchial Lavage at Dr. Essa Lab

MTB by GeneXpert – Bronchial Lavage at Dr. Essa Lab

The MTB by GeneXpert – Bronchial Lavage at Dr. Essa Lab is a state-of-the-art molecular diagnostic investigation designed for the rapid, highly sensitive, and specific detection of Mycobacterium tuberculosis (MTB) complex DNA. Conducted at Dr. Essa Lab in Karachi, Pakistan, this advanced test simultaneously identifies mutations associated with resistance to rifampicin (RIF), a cornerstone first-line anti-tuberculosis medication. By utilizing bronchial lavage (BL) or bronchoalveolar lavage (BAL) fluid, this test provides critical diagnostic utility for patients presenting with suspected pulmonary tuberculosis who cannot produce sputum or who have repeatedly tested negative on traditional sputum smear microscopy.

The technology powering this investigation is the GeneXpert MTB/RIF assay, a cartridge-based nucleic acid amplification test (CBNAAT) developed by Cepheid. This automated system integrates sample processing, nucleic acid extraction, amplification, and target sequence detection using real-time polymerase chain reaction (PCR). The assay targets the rpoB gene of Mycobacterium tuberculosis, which is the hot-spot region for mutations conferring rifampicin resistance. By automating the entire process, Dr. Essa Lab minimizes the risk of cross-contamination, enhances diagnostic accuracy, and significantly reduces the turnaround time from days or weeks (required for traditional mycobacterial cultures) to just a few hours.

Evaluating bronchial lavage fluid is of paramount clinical importance in modern pulmonology and infectious disease management. Bronchial lavage is obtained during a bronchoscopy, a procedure where a flexible bronchoscope is passed into the lower respiratory tract, allowing direct visualization of the airways and targeted instillation and aspiration of sterile saline. This specimen represents a highly concentrated sample from the lower alveolar spaces, bronchioles, and bronchial tree, capturing cellular debris, inflammatory cells, and pathogens directly from the site of active pulmonary pathology. Consequently, the diagnostic value of performing a GeneXpert assay on bronchial lavage fluid is exceptionally high, particularly in paucibacillary infections, miliary tuberculosis, and cases involving immunocompromised patients, such as those living with HIV or undergoing chemotherapy.

Clinical Procedure: What to Expect

Patient Preparation

Because the collection of bronchial lavage fluid requires an invasive bronchoscopy procedure, meticulous patient preparation is essential to ensure safety and sample quality. Patients must adhere to the following guidelines prior to the procedure:

• Fasting Requirements: Patients must remain nil per os (NPO), meaning nothing by mouth (including water), for at least 6 to 8 hours before the scheduled bronchoscopy to minimize the risk of pulmonary aspiration during sedation.
• Medication Adjustment: Patients must inform their physician of all ongoing medications. Antiplatelet agents, anticoagulants (such as warfarin, heparin, or novel oral anticoagulants), and nonsteroidal anti-inflammatory drugs (NSAIDs) may need to be temporarily discontinued several days prior to the procedure to mitigate bleeding risks, under strict medical supervision.
• Medical History Disclosure: A complete medical history, including allergies to local anesthetics (like lidocaine), sedatives, or contrast agents, as well as cardiac or respiratory conditions, must be disclosed to the clinical team.
• Pre-Procedure Investigations: Baseline laboratory tests, including a complete blood count (CBC), coagulation profile (PT/INR, APTT), and a chest X-ray or CT scan of the chest, are typically reviewed before the procedure.
• Arranging Transportation: Since conscious sedation or local anesthesia is administered during bronchoscopy, patients must arrange for a responsible adult to accompany them home after the procedure.

During the Procedure

The clinical procedure is divided into two distinct phases: the clinical collection of the bronchial lavage fluid by a pulmonologist and the subsequent molecular analysis at Dr. Essa Lab.

The sample collection takes place in an endoscopy suite or bronchoscopy room. The patient is positioned comfortably, usually lying flat on their back or semi-reclined. Vital signs, including oxygen saturation, heart rate, and blood pressure, are continuously monitored. A local anesthetic spray (typically lidocaine) is applied to the back of the throat to suppress the gag reflex, and mild conscious sedation is administered intravenously to ensure patient comfort. The pulmonologist carefully inserts the flexible bronchoscope through the nose or mouth, passing it through the vocal cords and trachea into the bronchial branches of the affected lung segment. Once positioned, a small volume of sterile saline (usually 20 to 50 mL) is instilled through the bronchoscope channel into the bronchus and immediately aspirated back into a sterile collection trap. This aspirated fluid is the bronchial lavage specimen.

Once collected, the specimen is immediately labeled and transported to the molecular diagnostics division of Dr. Essa Lab under strict temperature-controlled conditions to preserve the integrity of the bacterial DNA. In the laboratory, the technician mixes the bronchial lavage sample with a specialized sample reagent containing sodium hydroxide and isopropanol. This reagent liquefies the sample and lyses the mycobacterial cells to release their DNA, while simultaneously inactivating the infectious pathogen to ensure laboratory biosafety. The treated sample is then transferred into a single-use GeneXpert cartridge. The cartridge is placed into the GeneXpert instrument, where the automated real-time PCR process takes place. The system performs automated fluidic processing, DNA extraction, purification, genomic amplification, and fluorescent detection of target sequences. The entire laboratory assay is completed within approximately two hours, after which a highly detailed molecular report is generated.

When is a MTB by GeneXpert – Bronchial Lavage Performed?

Suspected Pulmonary Tuberculosis with Negative Sputum Smears

Physicians frequently request this test when a patient presents with classic clinical symptoms of pulmonary tuberculosis—such as a persistent cough lasting more than three weeks, hemoptysis, night sweats, unexplained weight loss, and low-grade fever—but repeated sputum smear examinations for acid-fast bacilli (AFB) yield negative results. Smear-negative tuberculosis is common in patients with low bacterial loads (paucibacillary disease). The GeneXpert assay on bronchial lavage fluid provides a significantly lower limit of detection compared to smear microscopy, allowing for the rapid identification of Mycobacterium tuberculosis DNA directly from the lower respiratory tract, thereby preventing diagnostic delays and the initiation of inappropriate therapies.

Evaluation of Non-Productive Cough or Inability to Produce Sputum

In many clinical scenarios, patients with suspected pulmonary tuberculosis are unable to produce an adequate sputum specimen. This is frequently observed in pediatric patients, elderly individuals, patients with severe neuromuscular weakness, or those presenting with isolated interstitial lung disease or early-stage cavitary lesions. When sputum induction fails or is clinically inappropriate, a bronchoscopy with bronchial lavage is performed to obtain a high-quality specimen directly from the affected lung segments. Performing the GeneXpert assay on this lavage fluid bypasses the need for expectorated sputum, offering an immediate and highly accurate molecular diagnosis.

Suspicion of Multidrug-Resistant Tuberculosis (MDR-TB)

Multidrug-resistant tuberculosis represents a severe threat to public health, particularly in endemic regions. If a patient has a history of previous tuberculosis treatment, has been in close contact with a known MDR-TB patient, or is failing to respond to standard first-line anti-tuberculosis therapy, a rapid drug resistance profile is urgently required. The GeneXpert assay is uniquely capable of detecting mutations in the rpoB gene of the MTB genome, which are highly correlated with resistance to rifampicin. Because rifampicin resistance is a reliable surrogate marker for multidrug resistance, this test allows clinicians to immediately identify drug-resistant strains and customize the patient’s therapeutic regimen without waiting weeks for conventional drug susceptibility cultures.

Immunocompromised Patients with Atypical Pulmonary Infiltrates

Immunocompromised individuals, such as those with HIV infection, patients undergoing active chemotherapy, organ transplant recipients on immunosuppressive drugs, or individuals on long-term systemic corticosteroids, often present with atypical clinical and radiological manifestations of pulmonary tuberculosis. In these patients, standard sputum smears are highly unreliable, and the differential diagnosis includes a wide array of opportunistic infections, such as Pneumocystis jirovecii pneumonia, atypical mycobacteria, and fungal pathogens. A bronchial lavage combined with GeneXpert molecular testing is critical in these complex cases to rapidly rule in or rule out active tuberculosis, ensuring timely and targeted antimicrobial intervention.

Unresolved Pneumonia or Chronic Lung Cavitary Lesions

When patients present with non-resolving pneumonia, persistent pulmonary infiltrates, or chronic cavitary lesions on chest imaging that do not respond to standard broad-spectrum antibiotic therapy, clinicians must investigate alternative etiologies, including tuberculosis and fungal infections. Bronchial lavage allows for direct sampling of the abnormal lung parenchyma visualized during bronchoscopy. Running the GeneXpert assay on this specimen assists the clinical team in rapidly differentiating tuberculosis from bacterial abscesses, bronchogenic carcinoma, sarcoidosis, or deep mycoses, thereby guiding definitive clinical management.

What Does a MTB by GeneXpert – Bronchial Lavage Detect?

The MTB by GeneXpert – Bronchial Lavage assay is designed to detect several critical microbiological and genetic parameters. Specifically, the test detects and evaluates:

• The presence of Mycobacterium tuberculosis complex genomic DNA in the bronchial lavage fluid.
• The absence of Mycobacterium tuberculosis complex DNA, ruling out active pulmonary tuberculosis within the limits of detection.
• Mutations in the 81-bp rifampicin resistance-determining region (RRDR) of the rpoB gene.
• The absence of mutations in the rpoB gene, indicating susceptibility to rifampicin.
• Indeterminate rifampicin resistance, which occurs when the bacterial DNA load is extremely low, preventing clear genetic profiling of the rpoB gene.
• Semi-quantitative estimation of the bacterial load in the specimen, categorized as “High”.
• Semi-quantitative estimation of the bacterial load categorized as “Medium”.
• Semi-quantitative estimation of the bacterial load categorized as “Low”.
• Semi-quantitative estimation of the bacterial load categorized as “Very Low”.
• The presence of internal PCR controls, ensuring that the amplification process was not compromised by enzymatic inhibitors.
• The adequacy of sample preparation and processing within the single-use cartridge.
• Distinction between Mycobacterium tuberculosis complex and non-tuberculous mycobacteria (NTM), as the probes are highly specific to MTB.
• Early-stage active mycobacterial replication in the lower respiratory tract.
• Paucibacillary pulmonary tuberculosis that is undetectable by routine light microscopy.
• Potential laboratory errors or invalid runs due to highly viscous or blood-stained lavage specimens.
• The presence of viable or non-viable MTB bacilli (since PCR detects DNA, clinical correlation is required to determine viability in post-treatment cases).
• Markers indicative of potential multidrug-resistant tuberculosis (MDR-TB) strains.
• Sub-clinical infections in patients presenting with normal chest radiographs but persistent respiratory symptoms.
• The presence of mycobacterial DNA in localized endobronchial tuberculosis lesions.
• A clear diagnostic baseline prior to the initiation of empirical anti-tuberculosis therapy (ATT).

Turnaround Time and Report Access at Dr. Essa Lab

At Dr. Essa Lab, we understand that a rapid diagnosis is critical for the effective management of tuberculosis and for preventing the transmission of the disease. The laboratory phase of the MTB by GeneXpert assay is completed within approximately 2 to 4 hours from the time the bronchial lavage specimen is received at our advanced molecular diagnostics facility in Karachi. However, the overall turnaround time may vary slightly depending on specimen transport logistics from various collection centers and the necessary quality control verifications performed by our consultant microbiologists.

Once the analysis is complete, the final report is reviewed, signed by a consultant pathologist, and immediately uploaded to our secure digital database. Dr. Essa Lab provides patients and referring physicians with multiple convenient methods to access diagnostic reports. Patients receive an automated SMS notification containing a direct link to download their report in PDF format. Reports can also be accessed securely through the official Dr. Essa Lab website by entering the unique patient lab number and password provided on the receipt. Physical copies of the reports can be collected directly from any of our conveniently located diagnostic centers across Karachi and other major cities.

MTB by GeneXpert – Bronchial Lavage Findings Overview

Structure / Parameter Evaluated	Normal Findings	Possible Abnormal Findings
MTB DNA Detection	Not Detected (Negative)	Detected (Positive) – Indicates active Mycobacterium tuberculosis complex infection.
Rifampicin Resistance	Not Detected (Sensitive)	Detected (Resistant) – Indicates presence of rpoB gene mutation; highly suggestive of MDR-TB.
Semi-Quantitative Load	Target Not Detected	Very Low, Low, Medium, or High – Reflects the concentration of mycobacterial DNA in the sample.
Internal PCR Control	Passed / Valid	Failed / Invalid – Suggests presence of PCR inhibitors (e.g., excess blood, mucin) or technical error.
Rifampicin Resistance Status	Not Applicable (if MTB is negative)	Indeterminate – DNA level is too low to accurately determine rifampicin resistance status.
Specimen Quality	Adequate volume, clear or slightly turbid fluid	Highly bloody, purulent, or insufficient volume, which may interfere with PCR amplification.
Clinical Correlation	No molecular evidence of active pulmonary tuberculosis	Molecular evidence of active pulmonary tuberculosis (sensitive or resistant to rifampicin).

Note: Diagnostic findings should always be interpreted by a qualified healthcare professional together with the patient’s symptoms, medical history, physical examination, laboratory investigations, previous imaging studies, and other relevant clinical information. Additional investigations or specialist consultation may be recommended depending on the findings.

Why Choose Dr. Essa Lab for MTB by GeneXpert – Bronchial Lavage?

• Pioneering Diagnostic Excellence: Established in 1987 by Prof. Dr. Essa M. Abdulla, Dr. Essa Lab is one of Pakistan’s most trusted diagnostic institutions, renowned for its commitment to accuracy and clinical integrity.
• Advanced Molecular Pathology: Our molecular diagnostics division is equipped with state-of-the-art Cepheid GeneXpert systems, ensuring the highest standards of PCR testing and molecular analysis.
• Expert Clinical Oversight: All molecular and microbiological tests are supervised and interpreted by highly qualified consultant pathologists and microbiologists with extensive clinical experience.
• ISO Certified Quality Systems: Dr. Essa Lab adheres to strict international quality management standards, maintaining robust internal and external quality control protocols.
• Rapid Turnaround Times: We prioritize critical infectious disease testing, delivering highly accurate molecular results within hours to facilitate prompt clinical decision-making.
• Convenient Digital Access: Patients and physicians can easily access, download, and share diagnostic reports via our secure online portal, mobile application, and automated SMS services.
• Extensive Network: With numerous collection centers across Karachi and Sindh, we offer unparalleled accessibility for sample drop-off and patient care.
• Compassionate Patient Care: Our dedicated staff is trained to provide a professional, comfortable, and supportive environment for all patients undergoing diagnostic investigations.

Frequently Asked Questions (FAQs)